Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selective mD5 agonist
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University School of Medicine
- Modality
- Small Molecules
01
Overview
Selective mD5 agonist is a brain-penetrant, non-catechol dopamine D1/D5 receptor agonist with a ~100-fold potency shift toward the mouse D5 receptor (mD5) over the mouse D1 receptor (mD1) [P632]. Developed by researchers at the Johns Hopkins University School of Medicine, the compound acts as an affinity-biased full agonist of mD5 with no detectable allosterism [P632]. It was designed as a pharmacological tool to help elucidate the relative in vivo functions of D5 and D1 receptors in rodent models, as the selectivity-determining residues in the ECL2 domain are divergent between D5 and D1 exclusively within the rodent family [P632].
- Other names
- selective brain penetrant agonist of mouse D5 receptor
02
Targets
DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on selective mD5 agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selective mD5 agonist.